Correspondence: Progression-Free Survival Benefit or Health-Related Quality-of-Life Advantage: Which One to Choose?

pdf

..... The authors’ assumption that patients with brain metastases
cannot be cured and that maintenance of HRQOL should be the
primary objective does not represent the reality: more prolonged PFS
and lower neurologic death rates have been observed in patients with
adjuvant WBRT.Patients with brain metastases constitute a heterogeneous group, including different solid tumors with different prognoses. These varying prognoses depend on primary disease situation, tumor burden, weight loss, and many other factors that affect survival, apart from disease control in the brain. Another important point that should be discussed is the efficacy and the toxicity of radiation dose and fraction used frequently during WBRT (30 Gy/3 Gy fractions). It is better to test the value of WBRT in a homogeneous group, such as
those with only lung cancer or only breast cancer, with controlled or
no systemic (extracranial) disease."